Definition and diagnostic criteria of clinical obesity.
Journal: The lancet. Diabetes & endocrinology
Volume: 13
Issue: 3
Year of Publication:
Affiliated Institutions:
Metabolic and Bariatric Surgery, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK; King's College Hospital, London, UK. Electronic address: francesco.rubino@kcl.ac.uk.
University of Washington, Seattle, WA, USA; Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Center for the Treatment of Obesity and Diabetes, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
Monash University Department of Surgery, Central Clinical School, Alfred Health, Melbourne, VIC, Australia.
Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Endocrinology, Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
International Medical Affairs, Eli Lilly, Basingstoke, UK; Diabetes and Endocrinology, University College London, London, UK.
Institute of Metabolic Science and National Institute for Health and Care Research, Cambridge Biomedical Research Centre at Addenbrookes Hospital, Cambridge, UK.
Obesity Prevention and Care Program, Department of Medicine, University Hospitals of Geneva, Geneva, Switzerland.
Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia; Weight Management Services, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Centre for Metabolism, Obesity and Diabetes Research, Department of Pediatrics, McMaster University, Hamilton, ON, Canada; McMaster Children's Hospital, Hamilton, ON, Canada.
Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India; National Diabetes Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation New Delhi, India.
Toranomon Hospital, Tokyo, Japan.
Department of Endocrinology, Woodlands Health, National Healthcare Group, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Department of Surgery, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Endocrinology and Diabetes, Alfred Health, Melbourne, VIC, Australia.
Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Pennington Biomedical Research Center, Baton Rouge, LA, USA.
CIBER Pathophysiology of Obesity and Nutrition, Girona, Spain; Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain; Hospital Trueta of Girona and Institut d'Investigació Biomèdica de Girona, Girona, Spain.
Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
Division of Endocrinology and Diabetology, Department of Medicine, University of Graz, Graz, Austria.
First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland.
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK; Department of Diabetes and Endocrinology, Chelsea and Westminster Hospital National Health Service Foundation Trust, London, UK.
Helmholtz Institute for Metabolic, Obesity and Vascular Research of Helmholtz Munich, University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
Department of Internal Medicine III, Carl Gustav Carus University Hospital Dresden, Technical University Dresden, Dresden, Germany; School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Institute of Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA, USA.
School of Population Health, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland; School of Public Health, Imperial College London, London, UK.
National Diabetes and Endocrine Center, Royal Hospital, Muscat, Oman; Oman Diabetes Association, Muscat, Oman.
Obesity Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Clinical Research Unit, Dasman Diabetes Institute, Dasman, Kuwait.
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nutrition and Obesities: Systemic Approaches, NutriOmics Research Group, INSERM, Sorbonne Université, Paris, France; Department of Nutrition, Pitié-Salpêtrière Hospital, Assistance Publique-Hospital of Paris, Paris, France.
VITAM-Research Center on Sustainable Health, Québec, QC, Canada.
Iverson Health Innovation Research institute, Swinburne University of Technology, Melbourne, VIC, Australia.
Regional Office for Europe, World Health Organization, Geneva, Switzerland.
Section on Obesity Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Division of Endocrinology, Columbia University Irving Medical Center, New York, NY, USA.
Claude Bernard Lyon University, Lyon, France.
Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seoul, South Korea.
Mexican Society of Obesity, Monterrey, NL, Mexico.
European Coalition for people Living with Obesity, Dublin, Ireland.
Obesity Action Coalition, Tampa, FL, USA.
Department of Community Health, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria.
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Science, Medical University of Silesia, Katowice, Poland.
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Translational Research for Diabetes, Lille University, Lille University Hospital, Inserm, Institut Pasteur Lille, Lille, France; Department of General and Endocrine Surgery, Lille University Hospital, Lille, France.
Helmholtz Munich, Munich, Germany; Technical University of Munich, Munich, Germany.
University of Pretoria, Pretoria, South Africa; Nectare Waterfall City Hospital, Midrand, South Africa.
Internal Medicine, Center for the Study and the Integrated Treatment of Obesity, Department of Medicine, University of Padova, Padua, Italy; Center for Metabolic and Nutrition Related Diseases,Humanitas Research Hospital, Milan, Italy.
Division of Diabetes & Nutritional Sciences, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK; Catholic University of the Sacred Heart, Rome, Italy; University Polyclinic Foundation Agostino Gemelli IRCCS, Rome, Italy.
Abstract summary
Current BMI-based measures of obesity can both underestimate and overestimate adiposity and provide inadequate information about health at the individual level, which undermines medically-sound approaches to health care and policy. This Commission sought to define clinical obesity as a condition of illness that, akin to the notion of chronic disease in other medical specialties, directly results from the effect of excess adiposity on the function of organs and tissues. The specific aim of the Commission was to establish objective criteria for disease diagnosis, aiding clinical decision making and prioritisation of therapeutic interventions and public health strategies. To this end, a group of 58 experts—representing multiple medical specialties and countries—discussed available evidence and participated in a consensus development process. Among these commissioners were people with lived experience of obesity to ensure consideration of patients’ perspectives. The Commission defines obesity as a condition characterised by excess adiposity, with or without abnormal distribution or function of adipose tissue, and with causes that are multifactorial and still incompletely understood. We define clinical obesity as a chronic, systemic illness characterised by alterations in the function of tissues, organs, the entire individual, or a combination thereof, due to excess adiposity. Clinical obesity can lead to severe end-organ damage, causing life-altering and potentially life-threatening complications (eg, heart attack, stroke, and renal failure). We define preclinical obesity as a state of excess adiposity with preserved function of other tissues and organs and a varying, but generally increased, risk of developing clinical obesity and several other non-communicable diseases (eg, type 2 diabetes, cardiovascular disease, certain types of cancer, and mental disorders). Although the risk of mortality and obesity-associated diseases can rise as a continuum across increasing levels of fat mass, we differentiate between preclinical and clinical obesity (ie, health illness) for clinical and policy-related purposes. We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health. Excess adiposity should be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (eg, waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, gender, and ethnicity. In people with very high BMI (ie, >40 kg/m), however, excess adiposity can pragmatically be assumed, and no further confirmation is required. We also recommend that people with confirmed obesity status (ie, excess adiposity with or without abnormal organ or tissue function) should be assessed for clinical obesity. The diagnosis of clinical obesity requires one or both of the following main criteria: evidence of reduced organ or tissue function due to obesity (ie, signs, symptoms, or diagnostic tests showing abnormalities in the function of one or more tissue or organ system); or substantial, age-adjusted limitations of daily activities reflecting the specific effect of obesity on mobility, other basic activities of daily living (eg, bathing, dressing, toileting, continence, and eating), or both. People with clinical obesity should receive timely, evidence-based treatment, with the aim to induce improvement (or remission, when possible) of clinical manifestations of obesity and prevent progression to end-organ damage. People with preclinical obesity should undergo evidence-based health counselling, monitoring of their health status over time, and, when applicable, appropriate intervention to reduce risk of developing clinical obesity and other obesity-related diseases, as appropriate for the level of individual health risk. Policy makers and health authorities should ensure adequate and equitable access to available evidence-based treatments for individuals with clinical obesity, as appropriate for people with a chronic and potentially life-threatening illness. Public health strategies to reduce the incidence and prevalence of obesity at population levels must be based on current scientific evidence, rather than unproven assumptions that blame individual responsibility for the development of obesity. Weight-based bias and stigma are major obstacles in efforts to effectively prevent and treat obesity; health-care professionals and policy makers should receive proper training to address this important issue of obesity. All recommendations presented in this Commission have been agreed with the highest level of consensus among the commissioners (grade of agreement 90–100%) and have been endorsed by 76 organisations worldwide, including scientific societies and patient advocacy groups.
Authors & Co-authors:
Rubino Francesco F
Cummings David E DE
Eckel Robert H RH
Cohen Ricardo V RV
Wilding John P H JPH
Brown Wendy A WA
Stanford Fatima Cody FC
Batterham Rachel L RL
Farooqi I Sadaf IS
Farpour-Lambert Nathalie J NJ
le Roux Carel W CW
Sattar Naveed N
Baur Louise A LA
Morrison Katherine M KM
Misra Anoop A
Kadowaki Takashi T
Tham Kwang Wei KW
Sumithran Priya P
Garvey W Timothy WT
Kirwan John P JP
Fernández-Real José-Manuel JM
Corkey Barbara E BE
Toplak Hermann H
Kokkinos Alexander A
Kushner Robert F RF
Branca Francesco F
Valabhji Jonathan J
Blüher Matthias M
Bornstein Stefan R SR
Grill Harvey J HJ
Ravussin Eric E
Gregg Edward E
Al Busaidi Noor B NB
Alfaris Nasreen F NF
Al Ozairi Ebaa E
Carlsson Lena M S LMS
Clément Karine K
Després Jean-Pierre JP
Dixon John B JB
Galea Gauden G
Kaplan Lee M LM
Laferrère Blandine B
Laville Martine M
Lim Soo S
Luna Fuentes Jesús R JR
Mooney Vicki M VM
Nadglowski Joseph J
Urudinachi Agbo A
Olszanecka-Glinianowicz Magdalena M
Pan An A
Pattou Francois F
Schauer Philip R PR
Tschöp Matthias H MH
van der Merwe Maria T MT
Vettor Roberto R
Mingrone Geltrude G
Study Outcome
Source Link: Visit source